Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Naptumomab estafenatox - Active Biotech

Drug Profile

Naptumomab estafenatox - Active Biotech

Alternative Names: ABR-217620; Anyara; TTS CD3

Latest Information Update: 05 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Active Biotech
  • Developer Active Biotech; NeoTX Therapeutics
  • Class Antineoplastics; Drug conjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Suspended Non-small cell lung cancer; Pancreatic cancer; Renal cancer

Most Recent Events

  • 10 Oct 2019 Phase-I clinical trials in Solid tumours (Combination therapy, Metastatic disease, Second-line therapy or greater) in Israel (IV) (NCT03983954)
  • 11 Feb 2019 NeoTX entered in a clinical trial collaboration for a planned phase Ib/II trial for Solid tumour
  • 21 Apr 2018 Active Biotech and NeoTX Therapeutics plans a phase Ib/II trial for Solid tumours (Combination therapy) in 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top